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precise modiﬁcation of the nucleic acid sequences in a genome.
Genome editing is typically performed using tools, such as mo-
lecular scissors, to cut a deﬁned location in a speciﬁc gene.
Genome editing has impacted various ﬁelds of biotechnology,
such as agriculture; biopharmaceutical production; studies on
the structure, regulation, and function of the genome; and
the creation of transgenic organisms and cell lines. Although
genome editing is used frequently, it has several limitations.
Here, we provide an overview of well-studied genome-editing
nucleases, including single-stranded oligodeoxynucleotides
(ssODNs), transcription activator-like effector nucleases
(TALENs), zinc-ﬁnger nucleases (ZFNs), and CRISPR-Cas9
RNA-guided nucleases (CRISPR-Cas9). To this end, we
describe the progress toward editable nuclease-based therapies
and discuss the minimization of off-target mutagenesis. Future
prospects of this challenging scientiﬁc ﬁeld are also discussed.https://doi.org/10.1016/j.omtn.2018.11.016.
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E-mail: subbroto@konkuk.ac.krInmodern biotechnological andmedical research, tools for precise and
predetermined genome modiﬁcation are used to identify genes with
diverse functionality. To study the functions of genes, small interfering
RNAs (siRNAs) arewidely used to suppress gene expression. However,
the use of siRNA-mediated knockdown is questionable because its
threshold success rate is below 70%.1 This method is hindered by
several issues, including low effectiveness of engineered constructs at
the chromosomal target, time-consuming processing, labor-intensive
selection criteria, and possible undesirable mutagenic effects.2
Although siRNA is useful to study gene function, the knockdown deﬁ-
ciency often occurs. siRNA-mediated knockdown offers temporary
inhibition of gene function, which limits our ability to correlate pheno-
type and genotype. In the early stages of molecular biotechnology,
genes were categorized by features of their mutant phenotype. Subse-
quent development of genome editing is more advantageous than the
siRNA technology for assessing the function of a gene or genotype.2,3
Currently, in addition to siRNA technology, modiﬁed DNA-binding
proteins, such as zinc-ﬁnger proteins and transcription activator-like
effectors (TALEs), have been widely used for sequencing target DNA
and for gene regulation.3–5 In modern biotechnological research, the212 Molecular Therapy: Nucleic Acids Vol. 14 March 2019 ª 2018 The
This is an open access article under the CC BY-NC-ND license (httpmethods for gene modiﬁcation primarily use three types of endonu-
cleases: zinc-ﬁnger nucleases (ZFNs), TALENs, and CRISPR-Cas9.
Recently, the use of CRISPR-Cas9 has increased tremendously
compared with that of other endonucleases (e.g., ZFNs and TALENs);
the latter are not used as frequently because of several drawbacks,
such as single-site targeting, occurrence of nonspeciﬁc mutations,
and low efﬁciency.6–10 Single-stranded nucleotide sequences with a
complementary sequence of approximately 20 pairs have been de-
signed to target a desired region in the genome.11,12 These three types
of endonucleases are based on similar mechanisms in modiﬁcation of
the genome, cleaving chromosomal DNA in a speciﬁc location for tar-
geted alteration of the genome.13
Site-speciﬁc programmable nucleases can generate DNA double-
strand breaks (DSBs),14 which can lead to 2-fold increases in ho-
mologous recombination.15 Therefore, site-speciﬁc programmable
nucleases can be employed in targeted mutagenesis.16 There are
two main mechanisms underlying DSB repair: non-homologous
end joining (NHEJ) and homology-directed repair (HDR). NHEJ,
the principal DNA repair mechanism found in eukaryotes, repairs
DSBs by ligating the broken ends of DNA. This ligation is mediated
by speciﬁc protein factors that re-connect the strand without a ho-
mologous DNA template.17,18 There are two major pathways in
NHEJ: (1) direct ligation of two ends of the targeted DNA, or (2)
end-joining via deletion or insertion of nucleic acids. In both of
these events, the occurrence of NHEJ-mediated deletions and muta-
tions are well documented.19,20 In contrast, HDR can also be imple-
mented to repair DSBs, but requires a homologous DNA template
(Figure 1).21–24 These mechanisms, however, cannot be used to
implement a gene knockin into non-dividing cells.25 Hence, aAuthor(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Genome Engineering Using Programmable Nucleases
Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas9 are used to induce targeted double-strand breaks (DSBs) at the
desired chromosomal locus. Non-homologous end joining (NHEJ) or homology-directed repair (HDR), one of the two cellular repair pathways, is then used to repair the DSB.
NHEJ can be used to knock out genes, whereas HDR can be used either for gene correction or to introduce precise alterations into the genome; this is directed by a
homologous DNA template. Adapted from Chandrasegaran and Carroll22 and Ramalingam et al.,23 copyright (2015) Creative Commons Attribution 4.0 International.
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geted integration (HITI), was developed for this purpose. Because
HITI does not require a homologous arm, it has a recognition
site for ﬂanking Cas9 so that Cas9 can cut both target and donor
sequences. The donor then integrates in the genome and repairs
DSBs in an independent pathway similar to that of NHEJ. This
technique has allowed integration of a gene into non-dividing cells
with only 2.1% insertion in the opposite direction.26
In early 2012, CRISPR-Cas9 nucleases were developed as a tool for
modifying the genomes of various cell lines and those of several living
organisms.27 For DNA modiﬁcation, CRISPR-Cas9 systems outper-
form the TALEN and ZFN systems.10,28–30 In addition to its editing
capability, the CRISPR-Cas9 system possesses curative potential31
and can be used to correct gene mutations in various genetic diseases
such as b-thalassemia, cystic ﬁbrosis, hemophilia, Duchenne
muscular dystrophy, and hereditary tyrosinemia type I.32–39 Systems
based on ZFNs, TALENs, and CRISPR-Cas9 have been used to alter
the genomes of plants, animals, and even humans. These tools are
now mainly used to alter the desired sequences in speciﬁc genes
and have impacted numerous ﬁelds, such as biopharmaceutical devel-
opment; gene surgery; alteration, regulation, and function of genome
structure; and production of biofuel, food, and transgenic cell lines
and animals (Figure 2). Although commonly used for genome alter-
ation, these tools still have numerous issues.In this review, we provide an overview of common genome-editing
nucleases including ZFNs, TALENs, CRISPR-Cas9, and single-
stranded oligonucleotides (ssODNs). These tools are used for genome
editing in various ﬁelds of cellular and molecular biotechnology,
including genome alteration in cells and embryos, development of
biocompatible drugs, targeting of genetic diseases, and development
of traits in plants or farm animals. Finally, we discuss the prospect
of using genome editing for editable nuclease-based therapies and
for limiting off-target mutagenesis. We also discuss the future pros-
pects of these technologies, including their use in genome editing
and modeling speciﬁc diseases.
Origin of Programmable Nucleases
Although double-strand breaks in the DNA cause severe fatal effects
in cells, DNA breaks can be repaired by NHEJ and HDR.15 Gene
targeting by HDR is not an efﬁcient mechanism in higher eukary-
otes. One in a million treated cells may undergo this kind of genome
modiﬁcation.21 Molecular scissors, such as restriction endonucle-
ases, cannot induce a DSB at a targeted chromosomal location.
This is because they can only identify very short DNA templates
of 4–8 bp. Inducing a targeted DSB is a major problem when em-
ploying HDR technology for genome engineering of eukaryotic
cells.22 This led to the development of a generalized delivery system
to target genomic DSB at a distinctive chromosomal locus and to
help stimulate HDR.22Molecular Therapy: Nucleic Acids Vol. 14 March 2019 213
Figure 2. An Overview of Applications of Genome Editing
Genome editing can be used in various fields of biotechnology, including biopharmaceutical development and gene therapy; genome structure alteration, regulation, and
function; and production of biofuel, food, and transgenic cell lines and animals.
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TALENs, and RNA-guided CRISPR-Cas9, have been used to induce
a targeted DSB. These programmable nucleases possess several
common features, which can be used in the editing of eukaryotic ge-
nomes. Using a rare-cutting endonuclease, DNA DSBs can be re-
paired via homologous recombination, which can improve the
repair by 2- to 3-fold efﬁciency in the targeted region. Conversely,
DSBs can also be repaired by NHEJ in the absence of a gene-
marking vector or homologous donor DNA.16,40 Programmable nu-
cleases for NHEJ- or HDR-mediated repair of site-speciﬁc DSBs are
commonly used for targeted genetic modiﬁcations, gene disruption,




Zinc-ﬁnger (ZF) motifs were ﬁrst described by Klug et al.42 as zinc-
binding domains in transcription factor IIIA in Xenopus oocytes;
ZFs occur more frequently in eukaryotes than in prokaryotes.42 Every
ZF is composed of approximately 30 amino acids in a conserved bba
conﬁguration, where the zinc atom is attached to two pairs of cysteine
and histidine residues. Furthermore, each ZF is combined with DNA
via an a-helix introduced into the main channel of the DNA double
helix, and by a recognized 3- to 4-bp sequence. Generally, most ZFs
are attached to a 3-bp target template and then change the recognition
site to a 4-bp cross-strand. This mechanism inﬂuences the speciﬁcity
of neighboring ZFs, thereby complicating the generation of ZF pro-
teins (ZFPs). ZFP generation is mediated by a simple modular design214 Molecular Therapy: Nucleic Acids Vol. 14 March 2019because all ZFs identify a triplet sequence (Figure 3A).22 To generate
DNA-binding ZFPs, three to six ZFs are linked together in a tandem
sequence (Figure 3A).22 ZFPs are generally composed of tandem ar-
rays of C2H2 zinc ﬁngers, which are mainly responsible for sequence
speciﬁcity of ZFNs.43 Altering DNA-binding speciﬁcities of ZFNs is
an important feature in construction of a programmable nuclease;
this is due to mutagenesis that can occur in ZFNs.44,45
ZFNs are generally composed of two important domains: the DNA-
binding ZF protein (ZFP) domain and the nuclease domain derivative
from the FokI restriction enzyme.46 A type IIS restriction enzyme,
FokI is usually used to identify non-palindromic pentadeoxy-ribonu-
cleotide in the DNA double helix. FokI cleaves the nucleotides down-
stream of the recognition site. The functionality of FokI is regulated
by two distinguishable protein domains: (1) domain FR and (2)
domain FN (Figure 3B).
22 The former is attached to a speciﬁc recog-
nition site in the DNA to help propagate a signal to the latter via allo-
steric interaction. Upon receiving the signal, the latter activates the
endonuclease activity of FokI after which the ﬁnal cleavage is induced
(Figure 3B).22 The modular characteristics of FokI endonuclease were
conﬁrmed by crystal structures of local FokI and DNA-binding FokI;
the cleavage domain was isolated from the recognition domain to pre-
vent any contact with DNA.47,48 Nevertheless, ZFNs produced by
traditional methods often showed limited DNA targeting activity
and cytotoxicity when off target.49,50 Studies on ZFNs have conﬁrmed
that, on average, a single functional ZFN pair can be generated per
100-bp DNA sequence,51 implying that ZFNs may allow efﬁcient
genome editing.
Figure 3. Illustration of DNA Recognition by ZFPs and Crystal Structures of FokI and How FokI Bound to DNA
(A) DNA recognition by ZFPs. (Ai) Structure of a single ZFN, (Aii) DNA recognition by ZFNs, and (Aiii) structure of three-finger Zif268 bound to its cognate site. (B) Crystal
structures of FokI and FokI bound to DNA. (Bi) Structures of FokI-DNA complex and of FokI enzyme alone. In both structures, the FokI cleavage domain piggybacks on the
recognition domain. (Bii) Native FokI crystallizes as a dimer. The dimer interface is at the FokI nuclease domain, which is formed by two salt bridges between arginine (R) and
aspartic acid (D) residues of the FokI monomers. Reproduced from Chandrasegaran and Carroll,22 Wah et al.,48 Miller et al.,300 and Pavletich et al.,301 copyright (2015)
Creative Commons Attribution 4.0 International.
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for searching possible ZFN target sites in a certain DNA sequence.
Among such programs, PROGNOS (http://bao.rice.edu/Research/
BioinformaticTools/prognos.html) and ZiFiT (http://ziﬁt.partners.
org/ZiFiT/) are most commonly used.52 In addition, EENdb (http://
eendb.cbi.pku.edu.cn/) can be used along with other databases.52
TALENs
TALENs are simple modular codes for DNA recognition processed by
the TALE proteins. TALEs are naturally occurring proteins
commonly found in Xanthomonas, a pathogenic bacterium that in-
fects plants.53,54 TALENs can act as a versatile platform for program-
mable DNA-binding proteins. There are several similarities between
TALENs and ZFNs. For example, similar to ZFNs, a FokI nuclease
domain is also found in TALENs. Moreover, TALENs utilize differenttypes of DNA-binding domains, mostly isolated from Xanthomonas
spp.13 The central domain of a TALE consists of a repeating unit
composed of approximately 34 amino acids. Each of these units is
recognized as a single base pair. The speciﬁcity of TALEs mainly de-
pends on the two hypervariable amino acids at the 12th and 13th po-
sitions, which are called repeat variable diresidues (RVDs).55,56
Four different RVD amino acid diresidues (i.e., NI, HD, NG/HG, and
NN) are mainly used to identify adenine (A), cytosine (C), thymine
(T), and guanine (G)/adenine (A), respectively. This recognition pro-
cess of TALEmodules appears to function independently from neigh-
boring modules, unlike the mechanism used by ZFPs. The presence of
a DNA recognition code mainly provides close interaction between
the array of amino acid repeats and the nucleotide sequence of a
genome; therefore, new TALENs can be blueprinted with desiredMolecular Therapy: Nucleic Acids Vol. 14 March 2019 215
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combined with the simple DNA detection code makes TALENs suit-
able for constructing common nucleases.59 Similar to programs
used to design ZFNs, web-based computer programs, such as
E-TALEN (http://www.e-talen.org/E-TALEN/),60 are also available
for designing TALENs.
In mammalian genomes, many types of complex TALENs can also
target distinctive loci. TALENs are generally simpler to construct
than are ZFNs. However, the designed sequences for encoding
TALENs are much longer than those for ZFNs. The TALE and
ZFN motifs are similar in size; however, TALE motifs recognize
only one base, whereas ZFNs recognize 3–4 bp sequences. These
consensus series of TALE motifs with highly repetitive sequences in-
crease the complexity of TALEN-encoding genes in E. coli,22 present-
ing a challenge in increasing the numbers of these genes. These
TALEN-encoding genes also complicate virus-mediated delivery
into mammalian cells. To overcome those challenges, different types
of effector domains can be combined with TALE repeats for targeted
genetic alterations.
Cloning DNA segments that encode TALE arrays involves certain
technical challenges posed by large similar repeat sequences, require-
ment of approximately 20 RVDs, and increased consumption of
cost.61 Numerous techniques for rapid assembly of custom TALE ar-
rays include: Golden Gate cloning systems,62 solid-phase assem-
bly,59,63 and ligation-independent cloning.64 All of these systems
are currently used for high-throughput sequencing. In brief, Golden
Gate cloning systems utilize a type IIS restriction enzyme for produc-
ing four-base extensions at individual DNA fragments encoding RVD
modules. DNA fragments with complementary extensions can be
linked to generate numerous RVD elements in a planned array.65,66
Any DNA sequences can be targeted by TALENs, which is the
main advantage of this type of nuclease over other types. Small
DNA sequences can be mutated using TALENs, which cannot be
accomplished by ZFNs or RNA-guided engineered nucleases
(RGENs). The one limitation for the synthesis of TALENs is that
the 50 ends of binding sites, which start with thymine (T), are recog-
nized by two amino acid terminal folds.55
To overcome this thymine-speciﬁc recognition, extensive research
has focused on TALE variants. Such efforts have made it possible to
help recognize bases other than thymine at the 50 end. This reorgani-
zation process has been useful for increasing the range of sites target-
able by TALENs.67,68 The production of customized TALENs or
genome-modiﬁed cell lines has been pursued actively by commercial
organizations such as Cellectis Bioresearch (Paris, France), Transpo-
sagen Biopharmaceuticals (Lexington, KY, USA), and Life Technolo-
gies (Grand Island, NY, USA).3
CRISPR-Cas9
A number of in-depth reviews have covered adaptive immunity in
bacteria, which involves the mechanism of adaptive resistance based
on the CRISPR-Cas system.69–77 Bacteria and archaea commonly use216 Molecular Therapy: Nucleic Acids Vol. 14 March 2019this mechanism to degrade complementary sequences that are pre-
sent in viral and plasmid DNA.78 These organisms generally capture
DNA fragments of approximately 20 bp from viruses and plasmids,
which facilitates the formation of a CRISPR sequence. These se-
quences, referred to as protospacers, can be inserted into their own
genome. Pre-CRISPR RNA is transcribed from CRISPR regions of
type II CRISPR systems belonging to two major classes. Pre-CRISPR
RNA is then processed to form a short CRISPR RNA (crRNA). This
process is facilitated by the transcription of trans-activating crRNAs
(tracrRNAs), which are combined with crRNAs.79 The crRNA-
tracrRNA complex ultimately associates with Cas9 to form an active
endonuclease for the degradation of foreign DNA; this active endonu-
clease is called dual RNA-Cas9.78 RNA-Cas9 targets a 23-bp sequence
that consists of a guide sequence (20-bp) in crRNA and the 50-NGG-
30sequence identiﬁed as the protospacer-adjacent motif (PAM).80
The crystal structure of Cas9 proteins, derived from different species,
can exist alone as an inactive form, although it can become active
through the binding of a single-chain guide RNA (sgRNA).81 A
new RGEN-encoding plasmid can be easily prepared by cloning
DNA sequences that encode either crRNA or sgRNA into a suitable
vector. This process is much simpler than complicated protein-engi-
neering methods for the synthesis of RGENs.82–84 Due to a basic
design and simple preparation methods, RGENs are more suitable
for targeting endogenous loci in human cells than are ZFNs and
TALENs. In the case of RGENs, only RNA needs to be designed,
rather than protein-engineering two nucleases to recognize the target
sequence. The CRISPR-Cas9 system is more advantageous for new
targets because it can target many objects simultaneously; this system
has been widely used in research laboratories worldwide. Moreover,
the CRISPR-Cas9 system is economical for small laboratories, making
it a reasonable choice for genome engineering procedures.22 In addi-
tion to its utility in editing genomic sequences, the CRISPR-Cas9 sys-
tem is a non-mutagenic gene regulation tool that is completely
sequence speciﬁc. Several companies, such as Sigma-Aldrich, System
Biosciences, ToolGen, and Transposagen Biopharmaceuticals,
commercially offer RGENs for laboratory use.
ssODNs
Engineering the mammalian genome is a powerful genetic approach
for developing novel therapeutics for treating hereditary diseases. In
addition to complete gene knockout, there is also single-nucleotide
exchange for re-engineering of mammalian genomes via ssODNs.
This method has been used to generate nucleotide changes and often
works in combination with other genome-editing tools.85–88 The
lower efﬁciency of ssODNs makes them incompatible for therapeutic
application. However, adjuvants can be used to enhance the fre-
quency of ssODNs. The overall activity of genome editing by ssODNs
can be improved approximately 5- to 10-fold by inducing double-
strand DNA breaks before introducing ssODNs.89–92 TALENs have
also been used in combination with ssODNs to exchange single nucle-
otides at speciﬁc sites in a gene.66,93–95 To repair single-point
mutations, combining TALENs with ssODNs is used to generate sub-
stantial changes at both genotypic and phenotypic levels.95–97
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tion of ssODNs by TALENs, which are required for gene editing of a
speciﬁc entry site provided for the oligonucleotide. An oligonucleo-
tide with an adjacent stretch of RNA and DNA has been developed
for correction of a single mutation in episomal and chromosomal tar-
gets in mammalian cells.98,99 This type of oligonucleotide is capable of
correcting a site-speciﬁc mutation in tissue-cultured cells when
administered in vivo. This stable and steady process of gene correc-
tion, mediated by an RNA-DNA oligonucleotide, was established
by clonal analysis at the sequence level.100 This RNA-DNA oligonu-
cleotide may be a promising curative approach for genetic diseases.
To inhibit the expression of a desired gene, ODNs can be used as anti-
sense oligonucleotides that hybridize with target mRNAs comple-
mentary to the sequence of the antisense oligonucleotide.101
In mammalian cells, a 40-nt ssODN is sufﬁcient for genetic modiﬁca-
tion.102,103 In yeast, however, 20–70 bases are needed to induce
modiﬁcations. A plasmid vector, bearing a mutant neomycin phos-
photransferase (NPT) gene, can be co-transfected with a 40-base sin-
gle-stranded oligomer that comprises the sequence of wild-type NPT
in mammalian cells. Cells containing NTP are selected by G418 anti-
biotic screening. These cells contain wild-type DNA molecules that
result from recombination between twoDNAmolecules. Thismethod
is advantageous in altering or introducing pointmutations into the ge-
nomes of human cells.102 In yeast, sense oligonucleotides generate
nearly 20-foldmore transformants than do antisense oligonucleotides.
This discrepancy was conﬁrmed with oligonucleotides designed to
create modiﬁcations at six different locations along the gene. The con-
trary result was likely caused by the length and sequence of the oligo-
nucleotide, number of alterations, and host strain.103 This implies that
ssODNs can be used in various gene-targeting approaches including
the development of transgenic animals, improvement of isogenic
cell lines, site-speciﬁc mutagenesis, and gene therapy.
Applications of Genome Editing in Mammals
In life sciences research, biotechnologies that enable deletion, inser-
tion, and modiﬁcation of DNA sequences in cells or organisms allow
us to evaluate speciﬁc gene functions. These genome-modiﬁcation
technologies have also enabled the examination and large-scale
manipulation of genes and protein networks. In addition to enabling
manipulation of transcriptional regulation at a speciﬁc locus, genome
editing can reveal themechanisms regulating genetic systems. Inmod-
ern biotechnology, the underlying regulatory mechanisms of genetic
building blocks are helpful for reverse engineering of useful biological
systems. The concurrent modiﬁcations of multiple genes can have
adverse effects that trigger complex polygenic disorders. Conversely,
genome-editing technologies can be used to directly correct harmful
mutations in humans.104 Potential applications of programmable nu-
cleases in humans are discussed below and overviewed in Figure 4.
Genome Editing in Farm Animals
With the rapidly growing population, there is an urgent need to
develop biotechnological approaches that enhance animal produc-
tion, while reducing the risks associated with climate change and/orenvironmental pollution. In the recent past, genotyping and whole-
genome sequencing improved our ability to analyze the genetics of
farm animals. Production of genetically edited pigs was a milestone
in genome manipulation of farm animals.105 In recent years, genome
editing has been performed via deletion, addition, andmodiﬁcation of
base pairs at targeted loci. All of these genomic alterations are perma-
nent and heritable in the following generations of livestock. Similar to
the process occurring in plant species, ZFNs, TALENs, and CRISPR-
associated endonuclease Cas9 (CRISPR-Cas9) are universally used to
modify gene functions via NHEJ.106–108 However, insertions and ad-
ditions via NHEJ can vary in size and sequence, making screening of
nonfunctional clones more difﬁcult.109 Speciﬁc genes of interest in the
genomes of cattle, sheep, and pigs have been edited to yield viable zy-
gotes and living animals. MSTN, the gene encoding myostatin, can
generate more extensive muscling in cattle, sheep, and pigs, whereas
the POLLED allele in cattle is commonly targeted for editing along
with protein-encoding genes such as RELA.110–115 Editing of the
CD163 gene for resistance to the porcine reproductive and respiratory
syndrome (PRRS) in pigs is a recent achievement and has been used
extensively in the production of PRRS-resistant pigs.116,117
Using ZFN for genome editing begins with the introduction of
plasmid DNA or mRNA encoding ZFN into the target cells or em-
bryos via microinjection or transfection.118 Then the translated
ZFN protein binds to its speciﬁc target sequence and cleaves the target
DNA by activating FokI nucleases at 30C. The binding of ZFN to tar-
geted loci is slow at a lower temperature, which affects cell-cycle pro-
gression.119 Insertion of ZFN-encoding plasmid DNA or mRNA can
potentially cause constant transcription, leading to nonspeciﬁc DNA
cleavage. In the case of ZFN-encoding plasmid DNA, a temporary
transfection protocol can be used to dilute the plasmid DNA; this is
a major advantage of using ZFN. Alternatively, microinjection of
ZFN-encoding mRNA is more accurate than transfecting with
ZFN-encoding plasmid DNA.120 Thus, microinjection of ZFN-en-
coding mRNA can reduce the risk for permanent assimilation of
ZFNs, making ZFNs more efﬁcient genome-editing tools than the
conventional approach.
Recently, transgenic pigs have been used as alternatives to mouse
models for evaluating human diseases and developing therapies; this
is because symptoms of classical diseases in mice do not fully mimic
those in humans. Pigs are more suitable models for investigating hu-
man diseases, such as cystic ﬁbrosis, diabetes, and cancer, because pigs
possess human-like genetic, anatomical, and physiological character-
istics.121,122 Pigs are also vital organ donors in generating xenografts of
human organs.123 Knockout pigs, engineered using ZFNs, generally
carry a hemizygous transgenic EGFP reporter allele. The endogenous
porcine gene (such as peroxisome proliferators activated receptor-g
[PPAR-g]) was the ﬁrst gene successfully targeted by ZFN. These types
of knockout pigs are useful in research on cardiovascular diseases.124
Biallelic knockout live pigs are produced by using ZFNs to target an
endogenous gene.125 Furthermore, cattle with knocked out b-lacto-
globulin (BLG), a major milk serum protein and allergen, have been
produced via gene targeting with ZFN.126,127Molecular Therapy: Nucleic Acids Vol. 14 March 2019 217
Figure 4. An Overview of Potential Applications of Programmable Nucleases
Programmable nucleases can edit the genome and reprogram genetic information, which consequently affects genome structure and function. This technology can be used
to produce farm animals, transgenic cell lines (i.e., embryos, stem cells, and induced pluripotent stem cells [iPSCs]), and transgenic plants.
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with ZFN mRNAs. Successful cell transfection is conﬁrmed using the
T7 endonuclease PCR to show that approximately 15% of the cells
carry a mutated variant, whereas 3% are positive for the biallelic
BLG gene knockout. The mutated BLG gene is also veriﬁed to detect
the existence of any off-target mutagenesis. These studies indicate
that speciﬁc genome editing with ZFNs in higher domestic animals
results in less off-target mutagenesis than do other similar
approaches.126
The Gram-negative bacterium Xanthomonas is a plant pathogen that
naturally produces TALEs.Xanthomonas infects numerous plant spe-218 Molecular Therapy: Nucleic Acids Vol. 14 March 2019cies such as rice, citrus, cotton, pepper, tomato, and soybeans.128 In
cattle, two important genes in ﬁbroblasts, viz. ACAN and GDF8,
can be modiﬁed using TALENs. ACAN is responsible for congenital
achondroplasia, whereas GDF8 (growth differentiation factor
8/MSTN) acts as a controller of muscular growth. Bovine ﬁbroblasts
bearing the GDF8 gene showed approximately 29% modiﬁcations
when treated with TALENs.101 Conversely, the ACAN gene showed
77% modiﬁcation after treatment with TALENs.101 To produce live
progeny with desirable genetic modiﬁcations, customized cells are
used for somatic cell nuclear transfer.110 Recently, TALENs were
used to generate a porcine model of hypercholesterolemia by modi-
fying the LDL receptor gene. TALEN-based alteration of the porcine
www.moleculartherapy.org
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dystrophy (DMD).110 To improve disease resistance in pigs, 20 ng/mL
TALENmRNAwas recently introduced into porcine zygotes to target
the RELA gene. Sixteen out of 56 porcine embryos were successfully
transformed. The RELA gene is involved in tolerance to infection
with the African swine fever virus.129 Successful transformation was
conﬁrmed by DNA sequence analysis. Among the mutants, one-third
was either homozygous or heterozygous. The genome sequences of
theMSTN locus in both cattle and sheep show a high level of similar-
ity; hence the same TALENs can be used in sheep and cattle.130 To
generate live progeny, TALEN mRNA was microinjected into ovine
zygotes and then transferred into recipient ewes. After successful
pregnancy and delivery, fewer offspring were found to have the het-
erozygous gene.130
The speciﬁcity and efﬁcacy of genome editing via CRISPR-Cas are
similar to those achieved using ZFNs and TALENs. The von Wille-
brand factor (vWF) gene in pigs has been targeted by injecting
Cas9 mRNA and sgRNA into zygotes. However, premature embry-
onic development was not affected by this process. After a successful
pregnancy and delivery, the survival rate of piglets was approximately
88%. In-vivo piglet fetal development was not hampered by this
genome modiﬁcation.131 Other genes, such as the p65 and the adeno-
matous polyposis coli (APC) gene loci, have also been targeted in
porcine fetal ﬁbroblasts by the CRISPR-Cas9 system.132 All of these
endonucleases act as valuable gene-editing tools that are revolution-
izing biological research and molecular medicine. To further expand
this technology, we need to investigate model organisms and farm an-
imals, develop biomedical models, and alter genes for the treatment of
genetic diseases.
Genome Editing in Embryos
All the discussed programmable nucleases can also be used as
genome-editing tools for human embryos. Altering genes in somatic
cells at various clinical phases can be helpful in developing potential
therapeutic applications. In recent years, CRISPR-Cas9 was used as a
therapeutic tool to prevent the onset of b-thalassemia (a fatal blood
disorder) by eliminating mutated human b-globulin (HBB) gene,
which is responsible for the onset of b-thalassemia.133 Nonetheless,
this approach was not successful because of the ethical issues raised
by the scientiﬁc community. To escape the ethical issues, it was
decided to use “non-viable” embryos, which were tripronuclear zy-
gotes generated by fertilization with two sperms. These non-viable
embryos are commonly discarded in clinics.134
In vitro fertilization may generate approximately 2%–5% polyspermic
zygotes, which can produce blastocysts; however, this does not man-
ifest in the in-vivo process.135 Polyspermic zygotes are a model for as-
sessing the target efﬁcacy and off-target effects of CRISPR-Cas9.136,137
A subunit of adult human hemoglobin is coded by the b-globin (HBB)
gene, which is mutated in b-thalassemia.138 The location of the HBB
gene on chromosome 11, within the b-globin gene group, consists of
four other globin genes: HBE, HBG2, HBG1, and HBD.139 Three de-
signed guide RNAs (gRNAs; G1, G2, and G3) can be transfected intohuman cells to target various sections of theHBB gene; in 29 indepen-
dent clones, speciﬁc editing of the HBB gene has been observed.134
Genome editing in germline cells or early embryos can offer an op-
portunity for the treatment of genetic diseases. Recently, the naturally
occurring C-C chemokine receptor type 5 (CCR5D32) allele was suc-
cessfully introduced into early human three pro-nuclei (3PN) em-
bryos using the CRISPR-Cas system. However, the efﬁciency of
HDR was low in the CCR5D32 allele.140 The CCR5D32 gene was cho-
sen because this gene encodes the major co-receptor used by the
HIV-1 virus in targeting human immune cells.141 People with this
allele show slow development of resistance to HIV infections.142,143
Subsequent procedures with premature human 3PN embryos gener-
ated 3PN embryos with the alteredCCR5D32 allele. Conversely, ZFNs
have been used without a speciﬁc rat gene for the production of
knockout rats.144 In this process, the GFP, immunoglobin M, and
RAB38 genes were targeted successfully to achieve the complete
knockout of GFP, immunoglobin M, and Rab38 transgenes without
any cleavage at off-target sites.145
Modiﬁcations of a genome, if introduced via its editing, can be heri-
table. Heritable alteration of the genome has been reported in rats af-
ter administering ZFN into one-celled embryos.146 Several studies
have generated multiple germline mutations in mice that turned
out to aid in the development of genetically engineered animals. In
mice, two loci, such as TET1 and TET2, can be targeted through
themodiﬁcations of CRISPR-Cas9. Treated parent mice have success-
fully transmitted this modiﬁcation to the next generation when
conﬁrmed by DNA sequencing.147,148
The genome-editing methods used in mammalian cells are not
completely similar to those used in model organisms such as zebra-
ﬁsh. The Cas9/gRNA system has been successfully used in embryos
to execute site-speciﬁc cleavage in zebraﬁsh. The successful exoge-
nous insertion of a foreign DNA fragment was then achieved as a
donor DNA was provided during the experiment. DSBs induced by
the Cas9 nuclease generate biallelic conversion of the ETSRP or
GATA5 gene in treated tissues. Microinjecting Cas9 mRNA and
gRNA into zebraﬁsh embryos leads to insertion of site-speciﬁc
1–24 bp or deletion of 7–32 bp. Cas9/gRNA has produced biallelic
conversion of ETSRP, GATA4, and GATA5 genes in targeted somatic
cells.149 In another study on zebraﬁsh, the CRISPR-Cas system was
used to target one hemizygous EGFP reporter gene and four endoge-
nous loci (TYR, GOL, MITFA, and DDX19).150 The resulting muta-
tion rate of 75%–99% indicates that in most cells, the biallelic gene
was disrupted. The ﬁve genomic loci in embryos were efﬁciently
modiﬁed by the biallelic gene to show diverse phenotypes. CRISPR-
Cas-induced mutations were highly speciﬁc in somatic tissues; addi-
tionally, germline transmission of these mutations has also been
conﬁrmed in the ﬁrst generation.150
Genome Editing in Stem Cells and iPSCs
Research on human induced pluripotent stem cells (iPSCs) and
human embryonic stem cells (ESCs) has advanced the study of
human genetics and cell-based therapies. Pluripotent stem cells canMolecular Therapy: Nucleic Acids Vol. 14 March 2019 219
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them suitable for cloning and genotyping. Genome-modiﬁcation
tools have been successfully used to introduce highly speciﬁc alter-
ations into iPSCs, rendering them distinguishable from background
noise; this allows assessment of numerous developmental and dis-
ease-associated characteristics. Genome editing in human iPSCs
aids in the production of synthetic organs and regenerative medicine,
as well as in gene therapies.152 Therefore, interest in modiﬁed human
iPSCs has increased because of their potential use in adapted cell
therapy.151,153
To study the gene functions in mice, researchers generally target ESCs
via homologous recombination (HR); however, similar to HDR, HR
was also unsuccessful in human ESCs.154 ESCs differ between humans
and mice, likely reﬂecting differences in DNA repair processes.
Although both ZFNs and TALENs have been shown to be successful
in editing iPSC genomes, cloning using CRISPR-Cas remains the
most straightforward technique. Despite the successful achievement
in targeting and modiﬁcation of genes, isolation of edited iPSC clones
was difﬁcult and expensive. However, genome modiﬁcation in treated
human iPSCs is currently easily demonstrated by microscopy or ﬂow
cytometry. After modiﬁed iPSCs have been identiﬁed and genotyped,
assessment should be made further for their pluripotency (extracel-
lular and intracellular) and any chromosomal abnormalities.153
Both human ESCs and iPSCs will likely play important roles in devel-
oping new technologies for modiﬁcations of the human genome.151
These technologies can also aid in engineering dendritic-cell-directed
cancer vaccines, T cell immunotherapy, and experimental biology.
Moreover, modiﬁable human ESCs and iPSCs can be used to create
human cell lines for increased production of biomolecules, which
have numerous industrial applications.155,156
Human monogenic diseases (e.g., sickle cell anemia, spinal muscular
atrophy, and X-linked adrenoleukodystrophy) can be easily treated by
gene complementation or alteration. Recently, several studies on hu-
man monogenic diseases have successfully used genome-editing tools
such as ZFNs, TALENs, and CRISPR-Cas9.155–159 Several gene ther-
apy approaches have been developed and used for effective treatment
of diseases such as X-linked severe combined immunodeﬁciency (X-
SCID), Wiskott-Aldrich syndrome (WAS), and adenosine deaminase
deﬁciency (ADA).153 Ex-vivo gene complementation of retroviral-
mediated gene therapy, which targets hematopoietic stem cells, has
been used to permanently correct X-SCID-related abnormalities.160
In an infection with the HIV-1 virus, CCR5 acts as a chemokine re-
ceptor that facilitates viral entrance into the host cell. Deletion of
32 bp at the coding region of this receptor renders it nonfunctional
and consequently resistant to HIV-1 infectivity.143
In other studies on HIV-1 infection in T lymphocytes or bone
marrow hematopoietic stem cells, modiﬁcation of the CCR5 receptor
was achieved using ZFNs in CD4+ T cells.157 This modiﬁcation even-
tually activates NHEJ machinery, resulting in random mutations. En-
forced expression of the four transcription factors, OCT4, SOX2,
KLF4, and c-MYC, in patient-derived ﬁbroblasts led to the develop-220 Molecular Therapy: Nucleic Acids Vol. 14 March 2019ment of disease-speciﬁc human iPSC lines. Speciﬁc demarcation of
such iPSCs enables the analysis of diseases such as Down syndrome,
also called trisomy 21.153 Modeling of Huntington’s disease (HD) has
also been performed using the CRISPR-based genome-editing tech-
nology and patient-derived iPSCs.158 To create a Parkinson’s disease
(PD) model, ZFNs were used to introduce two-point mutations into a
particular type of a-synuclein gene of human ESCs known as A53T.
This is a dominant mutation in a-synuclein as commonly observed in
a PD patient. As such, it is crucial evidence to acknowledge the spo-
radic form of the PD or less familial pattern of molecular pathogen-
esis.161 However, successful alteration of 1 bp restored the A53T
mutation in patient-derived iPSCs without affecting the rest of the
genome.161 Several similar genome-editing studies have been per-
formed in iPSCs.153 In one such study, a genome-editing tool was
used to correct or disrupt a gene via point mutation.153 These studies
have also generated novel models for diseases such as Barth syn-
drome, HIV, and b-thalassemia.153 Moreover, innovative research
has been conducted with artiﬁcial nucleases. Most of the prior work
has been aimed at increasing the efﬁciency of gene editing and devel-
oping a highly modiﬁed iPSC/ESC line.153 The revolutionary research
on this approach formed a TALEN-mediated Cas9-inducible human
ESC line. Six different genes in this cell line were targeted using
CRISPR, ultimately generating a double- or triple-knockout line.162
For therapeutic applications in patients with genetically linked dis-
eases, genome editing is promising for the correction of disease-
linked mutations in iPSC-derived progenitor cells. However, this
approach is currently limited by the lack of well-established protocols.
Therapeutic Applications
The development of genome editing for therapeutic applications is
challenging. Consistent alterations in multiple genes can have severe
effects that induce complex polygenic disorders, which can be treated
using advanced genome engineering tools such as ZFNs, TALENs,
and CRISPR-Cas9. The therapeutic applications, possibilities, and
challenges associated with programmable nucleases are illustrated
in Figure 5.
Treatment of Hematological Disease
Inherited Hematological Disorders Gene therapy has been used for
various human diseases, including hematological disease, cancer,
AIDS, diabetes, heart failure, and numerous neurodegenerative dis-
eases. More than 2,000 clinical trials using gene therapy have been
carried out worldwide.163 Several gene therapy products have been
approved for marketing; these include Gendicine in China, Cerepro
in Europe,163 Luxterna,164 and chimeric antigen receptor-modiﬁed
T cells (CAR-T cells) in the United States.165 Hematological diseases
include genetic diseases and different types of malignancy. In order to
develop a therapy for a genetic disease, it is necessary to identify a
mechanism that can be used to overcome the effects of the causative
mutation. The generation of iPSCs from patients with b-thalassemia
has been performed using a non-viral method and a TALEN-based
modiﬁcation.166 Modiﬁcation of the mutation in these iPSCs can
correct the function of the HBB gene. After sequencing, the HBB
gene of targeted iPSCs did not show any additional mutations. This
Figure 5. Schematic Diagram of Potential Therapeutic
Applications of Genome Editing
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b-thalassemia.166
Similarly, the genome-editing mechanism of CRISPR-Cas9 was also
used to correct the b-thalassemia mutation.167 In that study, the tar-
geted cells showed a normal karyotype with proper pluripotency
and no off-target mutations. The corrected human iPSC lines retain
their expression of HBB, which suggests potential clinical applica-
tion in gene therapy for b-thalassemia.167 Sickle cell disease
(SCD), another common genetic condition, is caused by a homozy-
gous mutation in the sixth codon of the HBB gene. In this mutation,
glutamic acid is replaced with a valine in the amino acid sequence.
The consequence is abnormal production of b-globin and faulty red
blood cells.168 Recently, a ZFN-based strategy was used to repair
two mutated b-globin alleles in iPSCs derived from a patient with
SCD.169 However, transcription of the repaired alleles was sup-
pressed by the co-integration of a gene cassette in the ﬁrst intron.169
This issue can be resolved by using a piggyback transposon, which
can facilitate the removal of this gene cassette in iPSCs without leav-
ing unnecessary sequences.168 Two TALENs were also designed to
target the HBB gene mutation in SCD.170 To correct the HBB
gene, CRISPR-Cas9 technology was used in iPSCs derived from pa-
tients with SCD. This genome-editing technology relies on a donor
template that includes the wild-type of HBB DNA, which shows
normal activity.171Molecular TA common blood-related genetic disease, hemo-
philia A, is caused by several mutations in the
blood coagulation factor VIII (F8) gene. Two
types of chromosomal inversions that cover a
fraction of the F8 gene normally result in approx-
imately 50% of hemophilia A.172 A particular
TALEN pair is used to convert a 140-kbp chro-
mosomal segment that passes through the F8
gene in human iPSCs; this segment is responsible
for hemophilia A. The modiﬁed segment can be
returned to the original state using the same
TALEN pair. The expression of F8 mRNA was
the same as that of wild-type in modiﬁed iPSCs
cell lines. The results of this study indicated
that a TALEN-based genome-editing mechanism
can help correct gene rearrangements that cause
genetic disorders such as hemophilia A.173
Another genetic disorder, hemophilia B, is caused
by the scarcity of blood coagulation factor IX,
which is encoded by the F9 gene. Mutations in
this gene generally occur in exons 2–8.174 Suc-
cessful repair of the mutated F9 gene was attained
using ZFN technology in vivo combined with a
targeting vector consisting of wild-type F9 exons2–8. The resulting gene targeting successfully repaired the hemophilia
B phenotype. The repair mechanism was consistent, and neither fail-
ure nor restoration of mutation had been reported.175
The phagocyte-NADPH oxidase enzyme complex includes a subunit
called phagocyte oxidase (phox), which can produce reactive oxygen
species (ROS). Mutations in phox cause the immunodeﬁciency
chronic granulomatous disease (CGD).176 The correction of X-linked
CGD (X-CGD) in iPSCs was accomplished using ZFNs. In this case,
ZFNs targeted a single copy of the therapeutic minigene GP91phox
located at the adeno-associated virus integration site 1 (AAVS1) locus.
Further studies have shown that the inserted AAVS1 alleles had no
off-target insertions, and that these clones were converted to mature
neutrophils with proper ROS production.177 The heterozygous muta-
tions in the RUNX1 gene can lead to an unusual autosomal dominant
disease called familial platelet disorder (FPD) and, further, to acute
myeloid leukemia (AML). This gene encodes an important transcrip-
tion factor that is involved in leukemogenesis. iPSCs of patients with
FPD and/or AML having a RUNX1 non-sense mutation Y260X
showed deﬁcient megakaryopoietic differentiation.178 To correct the
Y260X mutation, the donor vector was comprised of a cDNA
sequence of exons 5–8 and two ZFNs speciﬁc for the RUNX1 gene.
This mechanism can correct FPD in the iPSC line to produce a
wild-type variant of the gene and restored megakaryopoietic
differentiation.178herapy: Nucleic Acids Vol. 14 March 2019 221
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bone marrow, causes hematological and solid malignancies.179 FA is
caused by a point mutation in the FA complementation group C
(FANCC). This mutation can cause aberrant splicing that removes
exon 4 from the FANCC gene.180 An in situ study of this gene muta-
tion was carried out using ﬁbroblasts derived from FA patients.181
These authors applied CRISPR-Cas technology to amend the FANCC
mutation for the intervention of the FA disorder. The results of this
study were satisfactory, generating a high rate of corrected clones
via HDR mechanism.181 Overall, the results of these studies indicate
that genome-editing technologies can potentially alleviate inborn he-
matological disorders.
Acquired Hematological Disorders In acquired hematological dis-
ease, genome-editing tools can be used to examine gene function
and to develop disease models. AML is a common myeloid disorder.
AML can be treated using CRISPR-Cas9 to remove the C4BPB gene,
which encodes the primary protein responsible for AML.28 Similarly,
ZFN genome-editing technology has been used to disrupt the Tet2
catalytic domain of the TET2 gene, which is responsible for myelodys-
plastic syndrome in zebraﬁsh.182 Conversely, myeloid malignant cells
with multiple gene mutations can be modeled using the CRISPR-Cas9
genome-editing technology. This technology allows the production of
animals with mutations in various genes. The majority of these mu-
tations are found in cases of myeloid malignancies.172 Genome-edit-
ing technology together with transcriptomic analysis can be used as a
novel approach to identify and conﬁrm genes responsible for drug
resistance in AML.183 Genome-editing technology can be used in
lymphoid malignancies as a new therapeutic approach.
Adult T cell leukemia (ATL) is enormously destructive to mature hu-
man T cells. A virus known as human T cell lymphotropic virus type 1
(HTLV1) is responsible for ATL.184 Currently, there is no vaccine
against HTLV1. A promising result was nonetheless obtained using
ZFNs to target the HTLV1 provirus and destroy virally infected cells.
The major advantage of this technology is the formation of two long
terminal repeats (LTRs) for each provirus; LTRs possess enhanced
binding afﬁnity for their targets.185 ZFN technology has proven to
be a promising tool to combat ATL. Burkitt’s lymphoma (BL) is a
latent viral infectious disease. The causal organism of BL is a herpes-
virus known as the Epstein-Barr virus (EBV). Recently, the CRISPR-
Cas9 systemwas used to disrupt the EBV genome in a BL cell line. The
results of that study indicated that CRISPR-Cas9 suppressed the ac-
tivity of EBV and restored the pathway of cellular apoptosis.186 BL
cell lines require MCL-1, an anti-apoptotic protein, for their func-
tioning and survival. The deletion of this protein by CRISPR-Cas9
technology induces apoptosis in the BL cell lines.187 Genome-editing
technologies can be used to achieve a better understanding of the mo-
lecular mechanisms involved in inherited and acquired hematological
disorders. However, in using these technologies, we need to optimize
gene delivery and avoid destructive off-target side effects.
Treatment of Hereditary Disease. Targeting a speciﬁc sequence is
challenging when correcting defective genes in patients with inherited222 Molecular Therapy: Nucleic Acids Vol. 14 March 2019disorders. Currently, gene therapy and RNAi have shown the greatest
precision in targeting speciﬁc sequences.188 This ability currently ren-
ders gene therapy and RNAi as the two most powerful therapeutic
tools for the treatment of hereditary diseases. Gene therapy involves
the reinstallation of omitted gene function via viral transgene expres-
sion. Optimized oligonucleotide designs showed a localized distribu-
tion with improved safety proﬁles. RNAi thus enabled the targeting of
numerous genes in one tissue simultaneously. RNAi suppressed the
expression of faulty genes by knocking down target mRNA. Gene
therapy and RNAi are thus currently used to treat severe combined
immunodeﬁciency (SCID), transthyretin-related hereditary amyloid-
osis, WAS, cancer, and age-related macular degeneration.189–195
However, these technologies still have limited efﬁcacy in treating
certain genetic diseases.188 To overcome these limitations, several
nuclease-based genome-editing approaches have been developed
and used for the potential treatment of hereditary diseases. Naturally
occurringmutations can confer resistance in non-monogenic diseases
such as cardiovascular disease, Alzheimer’s disease (AD), and
hemoglobinopathies.34
Genome-editing technologies are efﬁcient tools for introducing pro-
tective mutations into affected individuals. NHEJ with programmable
nucleases was successfully used to inactivate theHTT gene in HD and
the FGFR3 gene in achondroplasia. In both cases, natural allele integ-
rity was maintained. Cell-culture models, currently used to study HD
and AD, and to develop suitable therapies against neurodegeneration,
are discussed later in this review. NHEJ-based technology was also
successfully used to treat nucleotide expansion disorders such as spi-
nocerebellar and Friedreich’s ataxia.188 HDR has also been used to
convert a mutant sequence to wild-type sequence in CCR5 in HIV
and PCSK9 in hypercholesterolemia.196,197 Mouse models are used
to assess the efﬁcacy of CRISPR-Cas9-mediated in-vivo genome edit-
ing in adult animals. Tyrosinemia type I (HTI) is a lethal genetic dis-
ease caused by a mutation in the enzyme fumarylacetoacetate hydro-
lase (FAH).34 A point mutation of G to A in the last nucleotide of exon
8, which leads to the exclusion of exon 8 during splicing, causes the
abnormality in mice and humans. The instability of the FAH protein
causes the accumulation of toxic metabolites, resulting in severe liver
damage.198 To correct the G-to-A splicing mutation of Fah protein in
the mouse model, single-strand DNA (ssDNA) was used along with
unguided Cas9 technology for the treatment of hereditary tyrosine-
mia.34 Another example is primate DMD. DMD is caused by three
different mutations in the dystrophin gene. These mutations result
in the loss of dystrophin and degeneration of primate muscle, similar
to the phenotype of DMD patients.199 CRISPR-Cas9 was delivered
directly into the muscle cells of mice with DMD using adeno-associ-
ated viral delivery. Once delivered, CRISPR-Cas9 excised the mutated
exon, generating an excised dystrophin. DMD mice that underwent
this treatment showed better muscle strength without off-target ef-
fects.200–202 In summary, the CRISPR-Cas9 system can be used as
an efﬁcient tool to correct or mitigate genetic diseases.
Treatment of Cancer. Cancer is a polygenic disease caused by defects
in multiple genes associated with oncogenes and tumor suppressor
Figure 6. A Schematic Diagram for Production of Genetically Engineered Mouse Models Using Programmable Nuclease (CRISPR-Cas9)
Genetically engineered mouse models (GEMMs) can be used to discover mechanisms of drug resistance and those of tumor initiation and progression, and to develop new
anticancer drugs.
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modeling cancer and uncovering genes that are responsible for the
overall process. Genetically engineered mouse models (GEMMs),
with speciﬁc mutations in genes, oncogenes, and tumor suppressors,
are used to study cancer biology.203 A phenomenon called passenger
mutations, occurring directly or indirectly, aids in the conversion of
normal cells into cancer cells by activating oncogenes or inactivating
tumor suppressor genes. CDNA-based overexpression and RNAi-
based inactivation can cause off-target effects. However, CRISPR-
Cas9 produces less off-target integration and, therefore, is frequently
used in cancer research. Different types of cell lines with one or more
targeted mutations are suitable for exploring the effects of mutations
associated with cancer phenotypes.
CRISPR-Cas9 technology also enables analysis of oncogenic signaling
pathways via sequential or multiplex gene editing.203 Using GEMMs
and non-germline GEMMs, researchers have uncovered the funda-
mental features of tumor instigation, maintenance, and evolution.
Moreover, these models can be used to screen anticancer agents
and identify drug-resistance mechanisms (Figure 6).204,205 Genome-
editing technology based on CRISPR allows us to generate large
stockpiles of ESC lines with numerous arrangements of basic or
restrictive mutations in oncogenes and tumor suppressor genes.The main advantage of the CRISPR-Cas9 system in mouse cancer
models is the systematic generation of models with multiple onco-
genic alleles. This property aids in assessing allele-speciﬁc tumor
development and therapeutic responses. The CRISPR-Cas9 method
is also used for improving existing cancer models. These next-gener-
ationmodels will help us to better understand and discover functional
remedies against cancer.203
In recent years, this system has also been used to edit the somatic
genome both ex vivo and in vivo. Ex-vivo editing of the TP53 tumor
suppressor gene has been performed in Em-Myc transgenic mice.206
A similar approach was used for ex-vivo disruption of the mixed he-
redity leukemia 3 tumor suppressor gene in AML.207 In another
study, CRISPR-Cas9 was used to rapidly generate mouse models of
AML by ex-vivo modiﬁcation of single or multiple genes via lenti-
virus.208 These studies showed that CRISPR-Cas9 ex-vivo somatic
genome editing can be used to rapidly produce mouse models of
several human malignancies. Similarly, CRISPR-Cas9 was used in he-
patocytes of living animals to deliver the plasmids of Cas9 and
sgRNAs, respectively, targeting the PTEN and TP53 tumor suppressor
genes in vivo.109 These studies show that somatic modiﬁcation of can-
cer genes by CRISPR technology in wild-type mice can proﬁciently
onset certain types of cancer.Molecular Therapy: Nucleic Acids Vol. 14 March 2019 223
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based technology offers efﬁcient delivery and editing via viral or
non-viral methods. CRISPR-Cas9 technology can be used to modify
T cells and the immune response.209 Additionally, this technology
may be used for speciﬁc ex-vivo manufacturing of immune cells for
potential immunotherapy. For example, new CAR-T cells possess
an introduced chimeric antigen receptor.210,211 In summary, the use
of CRISPR-Cas9 technology in cancer biology has allowed us to shift
from fundamental research to experimental and translational
applications.
Several viral infections are involved in carcinogenesis; these include:
(1) hepatitis B and C viruses in liver cancer, (2) EBV in nasopharyn-
geal carcinoma, and (3) human papillomavirus (HPV) in cervical
cancer. Inactivation of these oncogenic viruses may alleviate tumori-
genesis.163 The CRISPR-Cas9 genome-editing system can be used to
alleviate such carcinogenesis via defense against oncogenic viral infec-
tions. Antiviral and anti-proliferative effects were obtained using the
CRISPR-Cas9 system inHPV-mediated cervical carcinoma and EBV-
mediated BL cells.186,212 In both cases, treatment with CRISPR-Cas9
inhibited proliferation of tumor cells while reducing the overall viral
load.
If cancer is treated as a genetic disease, CRISPR-Cas9 can be used as a
genome-editing tool to correct oncogenic abnormalities in the
genome. Collaboration between genetic mutations and epigenetic al-
terations may cause the initiation and progression of cancer. CRISPR-
Cas9 can be used to correct genetic mutations in monogenic diseases
and transform the epigenetic states of a cell.163 With the help of
sgRNAs, dead Cas9 (dCas9; a Cas9 should lose endonuclease activity
due to point mutations at the endonuclease domains) and epigenetic
modiﬁers can enter target sites for epigenetic regulation; this is a pro-
spective tool in anticancer therapeutics. Recently, there has been
increased interest in improving anticancer immune responses, and
resistance to chemotoxicity and radiotoxicity. Cancer is polygenic
and heterogeneous in nature; this presents the main obstacle in
CRISPR-Cas9-mediated cancer therapy.163
Bladder cancer is a common urologic cancer that can be mitigated by
traditional chemotherapy and radiation treatment. However, the lim-
itations of these traditional treatments include: (1) mass cell killing,
(2) nonspeciﬁc targeting, (3) serious side effects, and (4) numerous
abnormalities of a genome.213 Recently, the CRISPR-Cas9 system
was used in combination with modular AND gate circuits, human
cancer-speciﬁc promoter of the telomerase reverse transcriptase
gene, and a human bladder-speciﬁc promoter gene. This circuit can
identify bladder cancer cells and is used to effectively treat bladder
cancer.214 The CRISPR-Cas9 genome-editing system can be used to
produce logic circuits. The Cas9 protein of the CRISPR-Cas9 system
can be joined with sgRNA to generate an effector complex that leads
to a double-strand DNA cleft.215 These circuits were shown to
robustly and precisely inhibit the proliferation of carcinoma cells in
the bladder; these circuits also restored apoptosis in these cells while
lowering their motility.216 Chromosomal relocation plays a vital role224 Molecular Therapy: Nucleic Acids Vol. 14 March 2019in the expression of genes that show therapeutic activity against
cancer.
In human non-small-cell lung cancer (NSCLC), the combination of
two oncogenes (echinoderm microtubule-associated protein-like 4
[EML4] and anaplastic lymphoma kinase [ALK]) was shown to play
an important role.216 Using CRISPR-Cas9 technology with a viral de-
livery method in somatic cells, researchers successfully rearranged the
chromosomes of adult mammals in vivo. This process produced a
mouse model of EML4-ALK-mediated lung cancer.217 These mouse
models provide information about the molecular mechanisms under-
lying tumor formation; this can be used to assess drug resistance and
the efﬁcacy of targeted therapeutics in vivo. Conversely, CRISPR-
Cas9-mediated technology for chromosomal rearrangement is limited
by spaces between the excised sites and their afﬁnity for Cas9.218 Colo-
rectal cancer (CRC), another commonly occurring human carcinoma,
is caused by several mutations in normal colon epithelium. The loss of
APC gene and successive mutations in KRAS (encoding Kirsten rat
sarcoma viral oncogene homolog), SMAD4 (encoding the SMADpro-
tein), and TP53 (encoding the p53 protein) genes are mainly respon-
sible for colorectal carcinogenesis. In a rodent model, mutations in
these genes were found to induce intestinal adenocarcinoma similar
to human CRC.219 Using CRISPR-Cas9 genome-editing methods, ge-
netic alterations can be introduced into human intestinal cells.82,215
sgRNAs and CRISPR-Cas9 can be used to target the APC, SMAD4,
and TP53 tumor repressor genes. This technology has also been
used to isolate single cells from human organoids and to generate mu-
tations that recapitulate the adenoma-carcinoma sequence.219
Treatment of Neurodegenerative Diseases. The most common
neurodegenerative diseases are mainly differentiated as either age-
reliant or selective neurodegeneration. The pathogenesis of common
neurodegenerative diseases, such as PD, AD, HD, amyotrophic lateral
sclerosis (ALS), and spinal muscular atrophy (SMA), remains un-
clear.220 To date, there are no effective therapies for these diseases.
However, the generation of cellular models will help acquire informa-
tion about the pathogenesis of these conditions and will lead to facil-
itated drug screening. Using stem cells for cell replacement was
recently explored as a possible therapy for these diseases. The preva-
lence of various neurodegenerative diseases is higher in developed
counties such as the United States (around 7 million occurrences).221
As mentioned earlier, genome-editing tools are used to prevent the
inheritance of AD. In future applications, it may be possible to use
these tools to develop curative therapies against neurodegeneration.
Genome-editing technologies, such as TALENs, ZFNs, and
CRISPR-Cas9, have already been used to alter or generate genetic
mutations and model particular neurodegenerative diseases
(Figure 7).222,223 In higher animals, it is difﬁcult to produce large-an-
imal disease models, necessitating the use of cell models. Additionally,
the lack of ESC lines, derived from large animals, is a major obstacle in
gene manipulation.220
Recent progress in genome-editing technologies has enabled the
production of large-animal models for exploring neurodegenerative
Figure 7. Schematic Illustration of the Use of Induced Pluripotent Stem Cells in Relation to Alzheimer’s Disease
(A) Induced pluripotent stem cells (iPSCs), derived from a skin biopsy acquired from a patient with Alzheimer’s disease (AD), are differentiated into neural progenitor cells and
neurons. (B) In familial cases, the disease-causing mutation can be corrected by gene editing of the iPSCs; the neural progenitor cells and neurons can be used for research
and drug screening. (C) Patients can benefit from cell therapy, better diagnostic procedures, customized treatments, and novel medical approaches. Reproduced from
Freude et al.,223 copyright (2014) Creative Commons Attribution 4.0 International.
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tions that impede the open reading frame and inactivate the gene.
Hence neurodegenerative diseases, caused by malfunction of speciﬁc
genes in animals, can be easily studied using CRISPR-Cas9.220
CRISPR-Cas9 genome-editing technology can also be used to assess
mosaic mutations in various types of cells. CRISPR-Cas9 can target
each gene in an embryo, which is advantageous in generating ani-
mal models of neurodegenerative diseases. This technique is partic-
ularly useful in large-animal models. Neurodegenerative diseases,
such as PD, can originate from mutations in the PARKIN and
PINK1 genes.In animal models, CRISPR-Cas9 can be used for targeted silencing of
candidate genes.220 This may enable us to mimic mutations observed
in patients with PD. Neurodegenerative diseases can also originate
from mutant cytotoxic proteins. PD and HD are partially caused by
mutations in a-synuclein and polyglutamine extended huntingtin,
respectively.220 Using CRISPR-Cas9 technology in mammalian cells
can efﬁciently generate these proteins, while other tools, such as
NHEJ, can be used to increase their production.224 Promising results
in human immunotherapy are also being reported. Human ALS is
frequently caused by the C9ORF72 gene, which encodes dipeptide
repeat (DPR) proteins. CRISPR-Cas9-based knockout screening ofMolecular Therapy: Nucleic Acids Vol. 14 March 2019 225
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hancers of C9ORF72-encoded DPRs. Using this technology,
numerous modiﬁers were identiﬁed; one of these modiﬁers, TMX2,
ameliorated endoplasmic reticular stress in a patient with C9ORF72
ALS, resulting in dramatic survival of neurons.225
Treatment of HIV. The ﬁrst case of HIV infection was reported in
1981.226 Since then, HIV has become a major public health concern,
affecting more than 35million people globally.226 Although antiretro-
viral therapy (ART) can reduce the symptoms of HIV-1, it is not
possible to achieve full recovery. The main obstacle for curative ther-
apy is perseverance of HIV reservoirs, which cannot be eliminated by
antiretroviral therapy.227 HIV viral DNA assimilates into host ge-
nomes, forming organized viral reservoirs. It is possible that deleting
or neutralizing viral DNA would eliminate HIV persistence.228 Some
limitations of current antiviral therapies include drug toxicity, resis-
tance to antiretroviral therapy, and failure to eliminate a dormant
viral infection. In addition, the medications and expenses of lifelong
treatment, as well as large numbers of patients with HIV/AIDS,
render treatment grueling and costly. To eliminate dormant viral res-
ervoirs, it is important to focus on individualized therapies that can
block viral DNA and show minimal drug toxicity.229
Nuclease-mediated genome editing is an encouraging approach in
therapeutic applications against HIV-1.229,230 The engineered nucle-
ases mainly include ZFNs, TALENs, and CRISPR-Cas9; these can
disrupt HIV-1 proviral DNA that has converted into active DNA
and integrated into the host genome. These technologies can also
interrupt the entry of HIV-1, which occurs via co-receptors C-C che-
mokine receptor 5 (CCR5) or C-C-C chemokine receptor 4 (CXCR4).
CCR5 can be targeted by ZFNs; this treatment for patients with
HIV-1 is in phase II medical trials.229,230 Because the entry of
HIV-1 requires co-receptors, such as CD4 and either CCR5 or
CXCR4, these co-receptors are potential targets for therapeutic appli-
cations. A deletion of 32 bp in the CCR5 gene of a patient with HIV-1
eliminated the existing infection and rendered the patient resistant to
infections with R5 type HIV-1.143,231
As discussed previously, antiretroviral therapy cannot eliminate HIV
from dormant reservoirs. Dormant viral reservoirs are mostly found
within memory CD4+ T cells and can persist for approximately 60
years after receiving antiretroviral therapy.232 The cleavage of
HIV-1 proviral DNA, induced via CRISPR-Cas9, is dose dependent
and does not show adverse effects in patients. The use of ZFNs has
also been successful in eliminating the HIV-1 provirus by targeting
the transactivation response element of HIV-1 LTR. However, using
ZFNs to eliminate proviral DNA needs to be further optimized by
protein engineering.155 The delivery of ZFNs into human CD4+ T
and CD34+ hematopoietic stem progenitor cells (HSPCs) to target
the CCR5 gene was assessed using a mouse model of HIV infection.
Using an adenoviral vector in patients with HIV showed promising
results. This vector expresses a ZFN and was used to target the
CCR5 gene in CD4 T cells isolated from 12 patients with HIV.104226 Molecular Therapy: Nucleic Acids Vol. 14 March 2019The CRISPR-Cas9 gene-editing system can also remove proviral
DNA by a sgRNA-guided method.233 This technology of proviral
DNA removal by CRISPR-Cas9 also helps to inactivate viral genes
in other diseases. CRISPR-Cas9-mediated removal of HIV proviral
DNA was achieved using sgRNAs, which can target preserved sites
within the U3 region of viral LTR in dormant infections.230 In addi-
tion to inactivation of proviral DNA and prevention of replication in
infected cells, CRISPR-Cas9 can provide resistance against recurrent
HIV infections and can target multiple spots inside the HIV
genome.234 The Cas9 protein of CRISPR-Cas9 can persist in human
HSPCs. HSPCs can then differentiate into monocytes and macro-
phages without undesirable side effects. TALENs and CRISPR-Cas9
can also be used for natural deletion of CCR5D32 in iPSCs with a
piggy-Bac transposon donor sequence.235
An HIV-GFP Jurkat cell line (JLat10.6) has also been used to test the
efﬁcacy of the CRISPR-Cas9 system in silencing HIV-1 DNA.236 The
results of that study indicated that CRISPR-Cas9 effectively targeted
and silenced HIV-1 proviral DNA in the JLat10.6 cell line. This
spurred the notion to match gRNA with a targeted viral DNA
sequence.236 Recently, internal antisense long non-coding RNAs
(lncRNAs) were tested as novel tools for inhibiting the HIV-1 provi-
rus, which was expressed from the NEF gene.229 High expression of
NEF lncRNA can cause viral inhibition, whereas low expression
shows the opposite result. The 50 LTR region may be a suitable target
for the CRISPR-Cas9 genome-editing system.229 Several antiviral
therapies can be used to control viral infections. However, the virus
is untraceable in the blood, which poses a major problem. Recent
studies show that the CRISPR-Cas9 genome-editing system can act
as a novel antiviral tool by targeting viral coding regions. The system
can be used to block assimilation and progression of HIV-1 infection,
to eliminate hidden viral reservoirs, and to confer lasting immuniza-
tion against HIV-1.
Application of Genome Editing in Plants
Crop Improvement
Traditional approaches to improving crop species have generally de-
pended on conventional and transgenic breeding methods. However,
these methods suffer from several limitations. The former is limited
by a declining genetic base that depends on germplasm collections.
In addition, randomly occurring variants are generated by mutagenic
effects. The latter generates genetically modiﬁed (GM) crops, which is
concerning with respect to health and environmental safety. The
addition of foreign genes into a genome can limit commercialization
and will possibly require a complex regulatory system. To overcome
these difﬁculties, newly introduced techniques based on site-speciﬁc
nucleases (SSNs) may be suitable tools for successful genome editing.
Genomemodiﬁcation in plants was ﬁrst conducted in the early 1990s;
however, due to the low efﬁciency of genome engineering, this
research did not advance. In recent years, precise genome modiﬁca-
tion in model plants and other important crops has been revolution-
ized with the help of SSNs.237,238 To date, research on SSNs has iden-
tiﬁed three common programmable nucleases: ZFNs, TALENs, and
Table 1. Practical Applications of Nucleases in Crop Plants
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Cotton embryogenic callus cells meganucleases 295 resistance to herbicide
Canola immature seed ZFN 296
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Wheat genomic DNA
CRISPR-Cas9 285




Sorghum immature embryos CRISPR-Cas9 284 expression of clover ﬂuorescence protein
Barley grains of winter barley
TALENs 298
creation of homozygous mutants
299
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ReviewCRISPR-Cas-mediated RNA-guided DNA endonucleases, which are
used for editing plant genomes (Table 1).3 Among these, the RNA-
based CRISPR-Cas system is the most suitable for use in various
organisms, especially in plants.239 The overall editing mechanism de-
pends on the introduction of DSBs at target sites commonly repaired
by either HR or NHEJ process.240 NHEJ can generate gene knockouts
by producing frameshift mutations in coding sequences; alternatively,
HR results in gene substitution, combination, or accumulation. To
date, most genome modiﬁcation procedures have mainly focused
on model plant species. As such, enormous efforts have been invested
into crop plant research. In the tobacco plant, resistance against one
or more herbicides was introduced by a missense mutation in donor
templates, which was then inserted into protoplasts along with ZFNs.
Similarly, the same ALS gene in a tobacco protoplast was replaced us-
ing TALEN-mediated genome modiﬁcation.241
Continuous expression of ZFN and a simple donor molecule add the
PAT herbicide tolerance gene at the IPK1 locus. This genome modi-
ﬁcation imparts herbicide resistance and leads to high accumulation
of phytate and low levels of inorganic phosphate caused by IPK1
expression.242 GM organism (GMO) crops have been commercially
used in the recent past. However, these crops are still not acceptedin the developed countries because of serious health and environ-
mental considerations. Conversely, speciﬁc manipulation of genomes
by SSN can be used to overcome problems associated with classical
transgenic breeding and can prevent the introduction of foreign genes
and proteins, reducing the probable risks associated with transgenic
procedures.243,244 The US Department of Agriculture (USDA; Wash-
ington, DC, USA) has provided public authorization to use ZFN tech-
niques for production of GM corn.245 The regulatory agenda for GM
crops in European Union (EU) countries is mainly focused on
genome modiﬁcation procedures rather than on ﬁnal products.
Therefore, crops modiﬁed by genome-editing tools, such as
CRISPR-Cas9 and others, may not be classiﬁed as GMOs.244,246
Finally, site-speciﬁc techniques can offer more accurate methods
for crop improvement and may be promising biotechnological tools
for plant breeding.
Trait Improvement
Without the domestication of plants, we could not maintain the bal-
ance between supply and demand or provide food, medicine, chem-
icals, renewable materials, animal feed, and biofuels. The process of
domestication includes improvement of crop performance and crop
properties that are directly related to human welfare. Genome editingMolecular Therapy: Nucleic Acids Vol. 14 March 2019 227
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fying genes that can directly improve the characteristics of crops.
Among genome-editing methods, CRISPR-Cas9 is more advanta-
geous because multiple traits can be customized simultaneously using
this procedure. The simplest form of gene modiﬁcation is NHEJ-
mediated gene knockout. This technique was successfully used to
eliminate genes that negatively affected food quality, decreased resis-
tance to pathogens or diseases, and decreased the value of end prod-
ucts.247 TALEN and CRISPR-Cas9 can be used to target genes located
at the mildew resistance locus (MLO) in the wheat plant. The MLO
homoalleles can be effectively knocked out to promote resistance to
powdery mildew in the wheat plant.248 SSNs enable the addition of
numerous genes near existing transgenic loci to facilitate stacking
of targeted molecular traits. This mechanism can introduce multiple
traits into crop plants with minimal risk of segregation, which is the
main obstacle in classical plant breeding and in modern genetic engi-
neering methods.
After stacking, the complete group of transgenes can be moved to
another plant because such a group acts as a solitary locus. A maize
line, containing an herbicide resistance marker and an artiﬁcial
ZFN target site, was produced using this process.249 CRISPR-Cas9
techniques are accessible and straightforward to use in both forward
and reverse genetics, aiding in basic research conducted with model
plant species. This is helpful for generating genomic data, and for
more rapid gene discovery and trait improvement in various plant
species.247 A modiﬁcation TALEN technique was developed by engi-
neering HAX3 from the Brassicaceae pathogen Xanthomonas cam-
pestris. These techniques have been widely used in many crop plants
including rice, barley, and maize. The genes that are responsible for
disease vulnerability in rice can be easily mutated by TALEN to pro-
duce disease-resistant rice with normal phenotypes.250 In rice,
numerous mutants have been produced using TALENs to knock
out eight Brachypodium genes with high efﬁciency.251
Genome-editing methods, such as CRISPR-Cas9, play a vital role in
identifying novel traits in common proﬁtable crop plants. The deliv-
ery and expression of engineered nucleases in plant cells are critical
because some plant species do not show positive results. For gener-
ating novel traits, it is important to establish a balance between the
speciﬁc plant tissue and the method used for transformation; this is
a major issue that needs to be addressed. To overcome these difﬁ-
culties, Gemini virus-mediated replicons can be used to transmit
DNA for genome engineering in various plant species.252 New ap-
proaches to plant breeding, along with in-depth understanding of
the whole-plant genome, will facilitate the development of important
traits in plants.
Minimizing Off-Target Mutagenesis Risks of Nucleases
Genome-editing nucleases are the multipurpose tools that are exten-
sively applied for studying the potential of genetic materials, produc-
ing GMOs, and preclinical investigation of genetic diseases. However,
the frequency of off-targeted activities (more than 50%) is a major228 Molecular Therapy: Nucleic Acids Vol. 14 March 2019concern in RGEN target sites, particularly in therapeutic and clinical
applications.253 To minimize the off-target mutations, a speciﬁc
proofreading approach needs to be elucidated. However, CRISPR-
Cas9 is reported as an editing approach with proofreading capability.
The mechanism of CRISPR-Cas9 was ﬁrst discovered in bacteria,
where it is used as an immune response against invading pathogens
such as bacteriophages.254–256 In the early stages of this discovery,
the CRISPR-Cas9 system was mainly used as a tool for genome edit-
ing in various types of cell lines. Later, living organisms, such as
C. elegans,255,257 zebraﬁsh,149 mice,258,259 rats,147,148 rabbits,260 and
monkeys,261 were more easily modiﬁed with CRISPR-Cas9 than
with TALENs or ZFNs. In humans, the CRISPR-Cas9 system can
also play an important role in correcting genetic mutations such as
those involved in b-thalassemia,32 cystic ﬁbrosis,262 hemophilia A,33
cataracts,263 hereditary HTI,34 and DMD.35
Numerous studies have shown that in human cells, nucleases are
involved in host defense mechanisms to ﬁght against viruses such
as hepatitis B264,265 and HIV.233–236 Frequent use of nucleases has
raised concerns about nonspeciﬁc activity at off-target sites, especially
when nucleases are used for clinical purposes. Nonspeciﬁc activity at
off-target sites may cause stable and injurious cytotoxicity or even
tumorigenicity, impeding normal cellular function in humans.
Nonspeciﬁc activity at off-target sequences is less frequent in the
case of CRISPR-Cas9 than in cases of ZFNs and TALENs.50,266–269
Off-target cleavage activity of CRISPR-Cas9 can be decreased by
mutagenesis-related approaches or by eradicating the nuclease func-
tion of CRISPR-Cas9. For deactivation of the RuvC nuclease domain,
an aspartate-to-alanine mutation is highly effective and attenuates the
activity of CRISPR-Cas9.254 In this procedure, just one strand is
cleaved off dsDNA, producing a simple gap rather than an entire
blunt dsDNA break, which is less efﬁcient in promoting HR.
Several groups have shown that the double-nick or DSBs strategy in-
creases cleavage at on-target sites; this can be used in combination
with wild-type (WT) Cas9, which effectively reduces off-target muta-
tions.270–272 This nicking activity may cause point mutations; hence
this process is also risky.273 The fusion of FokI nuclease with an inac-
tive Cas9 protein can control the genome-editing process. In the
gene-editing process, both Streptococcus pyogenes Cas9 (SpCas9)
and Staphylococcus aureus (Sa) Cas9 have been used extensively.
However, the speciﬁcity and cleavage activity of SaCas9 is higher
than that of SpCas9; this is because the former can be guided to a
21- to 23-nt site, whereas the latter can only recognize a 17-nt
sequence.274,275
Combining the Cas9 protein and sgRNA-mediated on- and off-target
cleavage has been used for DNA plasmid transfections in different cell
lines. This process results in overexpression of the Cas9 protein and
sgRNA, which may cause off-target mutagenesis because larger
amounts of DNA are transfected.29 As the number of interactions in-
creases, the chances of off-target site cleavage by Cas9 binding also in-
crease. Direct delivery of Cas9 into cells has been used to reduce the
off-target effects. The Cas9 protein is unstable and has a moderately
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instead of the Cas9 plasmid produces 13 times more on-target cleav-
age compared with off-target cleavage.276 In a 72-hr time-course
experiment, the Cas9 protein was no longer detected after 24 hr,
whereas a noticeable increase in Cas9 plasmid transfection persisted
for up to 72 hr.276 Chemical modiﬁcation at the 30 end of sgRNAs im-
proves their cleavage activity and speciﬁcity during genome
editing.277
Future Prospects of Genome Editing
As we have shown, genome-editing technologies have the potential to
signiﬁcantly advance cell-based therapy and improve our under-
standing of many genetic diseases. Efforts made over the last decade
are leading to the generation of speciﬁc and permanent multiple-hit
pluripotent cell (PC) lines for reprogramming into disease-linked
cell types. However, well-developed protocols for these methods are
still lacking. It is important to optimize this methodology and to
achieve competent gene alteration and biallelic gene editing before
translating these approaches into clinical applications. In a few
studies, the relative effectiveness of gene editing was compared among
the available options such as ZFNs, TALENs, and CRISPR/Cas9.
Recently, it was shown in human pluripotent stem cells (hPSCs)
that the CRISPR-Cas9 system is more effective than TALEN-medi-
ated gene editing.83
In some cases, a combination of techniques is preferable to
using traditional approaches to improve efﬁciency; examples of
such combinations are integrase-defective lentiviral vectors
(IDLVs)/ZFN,278,279 transposon/CRISPR,32 and TALEN/CRISPR
(iCRISPR).162 For patient therapy, genome-editing approaches
must precisely target disease-associated mutations in either iPSC-
derived progenitor cells or in mature cells for autologous transplant;
these procedures must be considered safe and not disturb other loci in
the genome. Interestingly, a complete genome analysis by Veres
et al.280 conﬁrmed that a slight risk of off-target mutations is posed
by both CRISPR-Cas9 and TALEN targeted to the sortilin 1
(SORT1) gene in human ESCs (hESCs). Presently, there are prom-
ising advances in gene alteration for a variety of diseases. Schwank
et al.262 recently corrected the function of cystic ﬁbrosis transmem-
brane conductance regulator (CFTR) gene using CRISPR-Cas9 in
adult stem cells (SCs) derived from patients with cystic ﬁbrosis (Fig-
ure 8). In that study, treatment with CRISPR-Cas9 generated few off-
target effects. The results of the forskolin-response assay, performed
in that study, conﬁrmed that the activity of disease-linked transmem-
brane receptor was recovered. However, cystic ﬁbrosis affects multi-
ple organs (Figure 8),262 making it difﬁcult to treat cystic ﬁbrosis
using the CRISPR-Cas9 system.
Recently, Sánchez-Rivera and Jacks203 predicted that nuclease-based
genome editing will be a vital link, connecting the bench and clinical
applications in cancer treatment. Successful expansion of genome
proﬁling for extensive characterization of patient-derived tumors
is creating comprehensive roadmaps for developing cell- and
whole-animal-based empirical approaches. Single or multiplexnuclease- and/or small-molecule-based technologies will advance
the development of personalized genome editing, which can be
used to rapidly recognize genotype-speciﬁc weaknesses and harmful
synthetic interactions.281 Such personalized techniques can poten-
tially enable rapid identiﬁcation of lethal mechanisms and develop-
ment of respective therapeutic approaches.282
Several technical restrictions limit the usage of CRISPR-Cas9 for ther-
apeutic targeting of oncogenes in human patients, and prospects of
this gene therapy are currently controversial. Recently, a study used
this technology to achieve accurate in-vivo genetic alterations in the
hepatic tissue of adult mice. This study successfully corrected an in-
herited genetic disorder via HDR in a mouse model.34 Future devel-
opments in this technology will permit therapeutic modiﬁcations of
single or various driver mutations. Such developments will also in-
crease the effectiveness of editing and delivery via CRISPR-Cas9 using
both non-viral and viral delivery vectors. In addition to modifying
cancer-linked mutations, CRISPR-Cas9 components can be em-
ployed for speciﬁc ex-vivo editing of immune cells for immunothera-
peutic applications. For example, CRISPR-Cas9 components can be
used to improve T cells modiﬁed with the chimeric antigen receptor
(CAR-T cells);210 in these cells, CAR is incorporated into a safe harbor
locus.
Currently, CRISPR-Cas9 is a leading RNA-programmed gene-editing
platform. The ﬁeld of genome alteration has undergone a rapid scien-
tiﬁc revolution that will transform basic biological and biomedical
research.254 Genome editing can be used in various types of iPSC-
based therapy and cancer therapy, offering exciting prospects for bet-
ter assessment of disease progression and development of effective
treatments.
Concluding Remarks
There is tremendous promise in using the CRISPR-Cas9 system for
targeted editing of the genome in cells and whole organisms. This
technique will advance human therapies, agricultural biotechnology,
and microbial gene engineering. The revolutionary discovery of the
CRISPR-Cas9 genome-editing system will impact the ﬁelds of modi-
ﬁed medicine, human genetic alteration, and drug development.
Nonetheless, various obstacles to genome-editing technology still
need to be overcome. The major concerns associated with genome
editing in higher organisms are off-target mutations in the genome
and precision in inserting Cas9 into a cellular system. Overcoming
these limitations will advance the ﬁeld of human gene therapy. Both
off-target mutations and imprecise delivery of Cas9 into the cell can
be lethal because they can cause cellular alterations and death.
Several studies have shown that Cas9-guided RNA complexes can
alleviate genetic disease when injected into an adult mouse model.
Traditional methods, such as nucleic acid and protein delivery,
can be helpful in identifying suitable delivery methods for
genome-editing nucleases. In addition to nucleases, supplementary
methods for genome editing have been considered. Recently,
another technology, called triplex-forming peptide nucleic acids,
was successfully used for genome modiﬁcations. These technologiesMolecular Therapy: Nucleic Acids Vol. 14 March 2019 229
Figure 8. Schematic Illustration Showing Functional Repair of CFTR by CRISPR-Cas9 in Intestinal Stem Cell Organoids Acquired from Patients with Cystic
Fibrosis
Reproduced from Schwank et al.262 Copyright 2013. Reproduced with permission from Elsevier.
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Reviewwill revolutionize the ﬁelds of medical and pharmaceutical sciences
by helping us identify biochemical pathways in infections and by
simplifying drug delivery methods. The limiting factors of genome
editing in animal and plant species need to be addressed before
application in humans because of the potential impact on human
welfare. Thus, detailed molecular studies and suitable disease
models are required before using genome editing in the treatment
of human diseases.
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